Imbruvica faces challenges on multiple fronts.

After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.

Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.

Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.